# Lotteries are an effective strategy for increasing booster uptake

Experimental evidence from Pakistan

Hina Khalid Agha Ali Akram Naeem Majeed Ashley M. Fox









# Lotteries are an effective strategy for increasing booster uptake: Experimental evidence from Pakistan

Hina Khalid PhD MPP,<sup>1§</sup> Agha Ali Akram PhD MA,<sup>2</sup> Naeem Majeed<sup>3</sup>, Ashley M. Fox PhD MA<sup>4</sup>

<sup>1</sup>Washington State Department of Social and Health Services, <sup>2</sup>Mathematica Policy Research, <sup>3</sup> Expanded Program on Immunization, Punjab Pakistan, <sup>4</sup>Rockefeller College of Public Affairs and Policy, University at Albany-State University of New York, Albany, NY

# § Corresponding author

Hina Khalid

Researcher

Washington State Department of Social and Health Services

Email: hinaaa.k@gmail.com

#### Coauthors

Agha Ali Akram Senior Researcher Mathematica Policy Research Email: agha.ali.akram@gmail.com

Naeem Majeed Technical Focal Person Expanded Program on Immunization, Punjab Pakistan nmajeed@gmail.com

Ashley M. Fox
Associate Professor
Rockefeller College of Public Affairs and Policy, University at Albany-State
University of New York
135 Western Avenue
Albany, NY 12203
Email: afox3@albany.edu

**Funding:** We would like to thank the International Growth Centre (IGC) for their generous support of this project.

#### **Declaration of interests**

We declare no competing interests.

**Ethical Approval**: The study received ethics approval from Research and Development Solutions (RADS), Pakistan.

**Acknowledgments:** The authors are thankful to Research Associate Sitara Gill for her work on this paper.

# Lotteries are an effective strategy for increasing booster uptake: Experimental evidence from Pakistan

#### **Abstract**

**Background**: Regular boosters will be necessary for the continued management of COVID-19, but current booster uptake is low in LMICs.

**Methods:** We conducted a field experiment at a large, urban hospital in Pakistan where we offered "opt-in" booster shots on-the-spot. Participants were randomized into one of four behavioral treatment messages, *vaccine mandates* (boosters may be required for travel, work), *side-effects minimization* (boosters have minimal side effects), *vaccine manufacturer* (updated choice of vaccines) and a *lottery arm* (a chance to win a cash-prize).

**Results**: The cash-prize lottery treatment showed the highest booster uptake (42 percentage points, p<0.01). Though smaller in magnitude, we found significant results for the *vaccine mandates* and *side-effects minimization* arms.

**Discussion**: The use of cash incentives may be a practical way to increase voluntary booster uptake when vaccines are also made easily and freely available to the public both for future pandemic preparedness but also for routine care.

#### Introduction

There is increasing recognition that regular COVID-19 boosters will be necessary for the continued management of the COVID-19 pandemic (1). Booster vaccination offers strong protection against COVID-19, particularly for older adults and people with chronic health conditions (2) (3). As the efficacy from primary vaccination wanes, absent regular boosters, especially among vulnerable segments of the population, it is possible that we will see recurring annual surges in COVID-19 hospitalizations.

Currently, COVID-19 booster uptake is low in most countries (4) and many low- and middle-income countries never achieved widespread uptake of primary COVID-19 vaccines. This is due to a combination of constrained access to vaccines and widespread vaccine hesitancy towards COVID-19 vaccines. Studies have found a number of contributors to COVID-19 vaccine hesitancy including concerns about vaccine safety and efficacy (5) (6) (7), belief that certain illnesses make one ineligible for vaccination (8), requesting time off from work to get vaccinated (9) (10), perceived health status and future-oriented anxiety (11), concerns about side effects, (12) occurrence of unwanted reactions after vaccination (13), perception that COVID-19 is just a conspiracy for boosting corporate profits, (14) and distrust in the government (15). Each of these attitudinal beliefs has contributed towards low uptake of the COVID-19 vaccines and boosters.

To counter widespread hesitancy and raise vaccination rates to levels sufficient to achieve herd immunity, many governments adopted various forms of vaccine mandates or passports to compel vaccination. Vaccine mandates have generally been found to have been highly effective at bringing up primary vaccination rates despite widespread hesitancy (16) (17) (18) (19). However, mandates have other downsides including the potential to seed suspicion and distrust of vaccines in ways that may be counterproductive to future vaccination efforts or may backfire (20). While mandates were arguably ethically justifiable at encouraging primary vaccination against COVID-19 (21), they may be less practical for encouraging booster uptake, especially as the

recommendations on booster frequency continue to evolve (22). It is unclear how perceptions of continued mandates might affect willingness to boost.

Efforts to encourage booster uptake will therefore face an even steeper challenges than primary vaccination given the widespread perception that the threat from COVID-19 has subsided (23) and the declining enforcement of COVID-19 vaccine mandates. An alternative to mandates, which are frequently considered unnecessarily coercive, are strategies grounded in the theory of behavioral "nudges." Behavioral nudges offer choice preserving alternatives to health mandates that aim to steer the public in health enhancing directions with minimal force by correcting cognitive biases in decision-making. Nudges can improve voluntary compliance with public health guidelines, including vaccinations (24).

Behavioral nudges that may be especially useful for increasing COVID-19 vaccine uptake include approaches that influence default choices (e.g., opt-out and opt-in vaccine offers), correct loss aversion associated with side-effects, positively frame the value of vaccines and use reward based financial incentives. However, which of these approaches is likely to be most effective, especially for booster uptake has received limited attention in the vast literature on overcoming vaccine hesitancy, despite its immediate policy relevance.

Convenience is a major factor that has been found to influence vaccine uptake (25). Simply making vaccination easily available or setting it as a default choice in a clinical encounter can have profound effects on uptake. Default options and opt-out approaches exploit the tendency of people to accept the status quo when an option is presented as standard or prescribed. Studies from other health interventions (i.e., HIV testing and organ donation) that use default options suggest that they may be a viable strategy to increase the uptake of COVID-19 vaccinations (26) (27). However, previous research indicates that using an opt-in approach may be preferable for more controversial vaccinations, such as HPV vaccines, where parents are more likely to consent when they can opt-in(28).

Other research centered around vaccine side effects finds that positive framing that minimize side effects (29) (30), messages about collective health consequences of not vaccinating (31), vaccine safety/efficacy (32) (33) and personal health benefits (34) can shape vaccine intentions. Framing of side-effects can especially play an important role in shaping vaccine intentions. For example, in a study in the UK found that positive framing of risk minimization increased booster intention for the unfamiliar vaccine but reduced intention for the vaccine previously received (35). Complementing risks of side-effects with equivalent risks from non-vaccination can correct probability neglect, or the tendency to overrate small risks and underrate larger risks (36).

Framing of the quality or efficacy of vaccines may also influence uptake as perceptions that COVID-19 vaccines are ineffective are a major reason provided for hesitancy to take the vaccines around the world. Research highlights that the type and source of vaccines can influence outcomes; a study in Jordan found that the Pfizer vaccine was the preferred choice (37), while in Bangladesh study participants were skeptical towards vaccines manufactured in India, US and Europe (38). A study from Brazil found that Brazilians, who overall have high vaccine acceptance, were more likely to reject vaccines developed in China and Russia, as compared to vaccines from the US or England. A study from Israel found that the general public was willing to accept any vaccine with efficacy is above 90% and a USA/UK country of origin rather than China or Russia (39) (40) (41). While mRNA vaccines have efficacy rates up to 95%, Chinese and Russian vaccines are of much lower efficacy. Yet, these are the vaccines that were initially most available in LMICs. National origins of vaccines can thereby serve as a cognitive short-cut signaling their likely efficacy.

Financial incentives have been found to be effective to promote a variety of health behaviors and have also been explored as a means to increase vaccine uptake (42). Lotteries are one type of financial incentive that have been used to increase COVID-19 primary vaccination. In theory, while cash incentives might help people change their behavioral health decision-making (43) (44) (45), studies on the association between

lottery programs and vaccine uptake have found mixed results (46) (47) (48) A study on Ohio's Vax-A-Million initiative found that the monetary incentive scheme led to an increase in the vaccination uptake in the state population (49). Similar results were found in a randomized controlled trial in Sweden, where monetary payments led to an increase in the vaccination rates (50). Yet, others only find a marginal impact of financial incentives in curbing vaccine hesitancy; a randomized controlled trial in California found that small monetary incentives and other behavioral nudges do not considerably increase vaccination rates (51).

While a number of studies have examined the use of lotteries in the U.S. context towards incentivizing primary vaccination (52) (53) (54), fewer studies have focused on the use of behavioral nudges and economic incentives in low- and middle-income countries, overall or to incentivize booster uptake (55).

In this study, we conduct a field experiment in Pakistan, a lower-middle income country in South Asia, to understand vaccine hesitancy and if behavioral interventions can lead to an increase in uptake of the COVID-19 boosters. The field experiment was conducted at a large, urban hospital in Pakistan where we offered "opt-in" booster shots on spot (outcome variable) and randomized behaviorally informed messages related to mandates, side-effects, quality of vaccines and financial incentives through entry into a lottery.

COVID-19 vaccinations have proved to be challenging in Pakistan over time. In February 2020, the Ministry of Health, Government of Pakistan confirmed the first case of COVID-19 in Karachi (56). COVID-19 vaccines were first rolled out in February 2021, however, vaccine hesitancy has been widespread among the population. In an attempt to encourage uptake, various measures were proposed, including restrictions on mobile access for the unvaccinated, mandatory proof-of-vaccination certificates for staff at schools and other public places, and travel restrictions for the unvaccinated (57) (58) (59) (60). COVID-19 booster shots were made available for individuals over the age of 30 in January 2022 to ensure continued protection against the virus (61). According to recent estimates, Pakistan has a population of 231 million. As of May 2023, 63.6

percent of Pakistanis had received the full vaccine dose, 74.9 percent had received at least one dose, and 23 percent had received a booster shot(62).

# **Study Data and Methods**

# Study design and participants

We conducted a five-armed randomized control trial at a large, urban hospital in Lahore, Pakistan, between December 21, 2022 and January 25, 2023. Randomization was carried out at the individual level. Enumerators collected data through a digital data collection platform, SurveyCTO. Verbal consent given by the participants was recorded digitally by enumerators on tablets. Respondents were given a nominal participation fee (Rs 100, USD 0.35).

Patients who visited the hospital for routine care were recruited as they entered the hospital. Our target population comprised individuals who had not previously received one or both doses of the booster shot, or had not gotten vaccinated against COVID-19. If participants met the eligibility criteria, their consent to participate in the survey was obtained. Participants were then randomly assigned to the control group or to receive one of the four behaviorally informed messages incentivizing them to receive the booster shot. Participants were asked a series of questions to understand vaccine preferences, and their demographic and behavioral characteristics. At the end of the survey participants were offered "opt in" booster shots; enumerators asked the participants if they were willing to sign up for the booster shot (or primary vaccination for those who were not previously vaccinated) during their visit to the hospital that day. (see Annex A & Annex B). Participants could then walk over to the vaccination site within the same hospital.

The treatment being administered to each respondent was not known beforehand by the enumerators as assignment to the behaviorally informed messages was done through the randomized sequence generated on SurveyCTO. Respondents were asked for their mobile phone numbers during the course of the study for disbursing the participation fee. A follow-up telephone survey was then administered on February 14, 2023 using the mobile phone information to assess whether they had received their vaccine or booster shot on the same day or subsequent to their visit. Both the surveys were designed in English and were translated in Urdu for better comprehension by the local population (see **Annex B**).

Support was received from a member of the government of Punjab's immunization team for conducting the study. In addition, the hospital management and staff gave permission to conduct the study and also agreed to give on site boosters. The Institutional Review Board Research and Development Solutions (RADS), Pakistan gave ethical clearance for this study.

# **Intervention groups**

The four intervention arms of the experiment were: Vaccine Mandates (T1) emphasizing that boosters may be required for certain travel destinations and work; *Side-Effects Minimization (T2)* focused on the safety of the vaccine/booster and minimal side effects; *Manufacturer of the vaccine* (T3) informed participants they could get Pfizer or Moderna versions of the booster and not the earlier Chinese or Russian vaccines and *Lottery (T4)* emphasized that if participants agreed to get the booster, their name would be entered in a lottery, a chance to win PKR 30,000 (see **Annex A**). After administering the treatment messages, the respondents were asked by the enumerators if they wanted to get signed up for the booster shot during their visit to the hospital that day. Respondents who said yes were given information about where to access the booster clinic. The consent for signing up for the booster shot is used as a measure of the participant's willingness/intention to get vaccinated.

#### Control arm

No behaviorally informed messages were administered to the participants in the control group. Rather, they were informed about the onsite clinic and asked about their intent to get signed up for the booster shot during their visit to the hospital that day.

#### **Outcome measure**

Our primary outcome captured an individual's willingness/intention to register for getting boosted. It is measured as a binary variable which takes on a value of 1 if the respondent consented to getting signed up for vaccination, and 0 otherwise.

## Follow-up survey

A short follow-up survey with a subset of 744 randomly selected participants was conducted via telephone on February 14, 2023 to ask if they had received the booster shot. We surveyed a subset of the original participants due to budget limitations.

There were two outcome variables which measured the 'uptake' of the COVID-19 booster shot: (i) *immediate vaccination* i.e., if the participant got vaccinated on the same day, and (ii) *subsequent vaccination* i.e., if the participant got vaccinated a few days later. The outcome variables are measured as binary variables and take on the value of 1 if the respondent got boosted and 0 otherwise.

# Statistical analysis

We calculate demographic characteristics for our sample and present them in **Table 1.** For our primary analysis, we used ordinary least squares (OLS) model to regress an individual's willingness to register for getting boosted. We examined whether exposure to different treatments was associated with willingness to get the COVID-19 booster shot. We also re-estimate the same model after controlling for individual participant level covariates.

We used the same model for data from our follow up survey sample, using two outcome variables: immediate uptake of the vaccine, and subsequent uptake of the vaccine. Robust standard errors were computed across all models. All analyses were conducted using STATA MP (version 17).

#### Results

# Main survey results

A total of 1,564 participants were approached and consented to participate in the survey. While 90% of respondents had received their primary vaccination, none had received the booster shot at the time of the study (**Figure 1**). Protection against COVID-19 (58 percent) and vaccine mandates (27 percent) were cited as the top two reasons for getting previously vaccinated. Concern about side effects (70 percent) and lack of trust in the vaccine (67 percent) were the top two reasons for hesitancy towards the COVID-19 vaccines among the 10% of the sample who had not vaccinated (**Table 1**).

The randomization procedure ensured that there was an equal split of participants among the treatment arms and the control group. (**Figure 1**). The sample was balanced on demographic characteristics. A summary of the key characteristics of the participants in the final analytic sample (total and disaggregated by treatment group) is presented in **Table 1**. (**see Annex C, Tables A1,A2**) The sample comprised of low to moderate income people, with slightly more females, but evenly balanced through the randomization. The full sample had 639 (41%) male participants and 921 (59%) female participants. Twenty-one percent of the respondents had never been to a school and 16 percent had completed high school. The average monthly income of respondents was PKR 34,000 (USD 149). Ten percent of the sample had never been vaccinated against COVID-19.

Across the full sample (n=1564), approximately, 16% (N=248) agreed to boost or vaccinate on spot after being delivered the randomized opt-in message. Approximately 4 percent(n=298) of participants in the control group were willing to register for the booster shot. By contrast, 45 percent of participants (n=151) in T4 (lottery arm) were willing to sign up for the booster shot. For T1 (vaccine mandates), T2 (side-effects minimization), and T3 (manufacturer of the vaccine), 11.64 percent(n=37), 9.08 percent (n=30) and 6.15 percent (n=19) of the participants were willing to sign up for the booster shot, respectively (**Table 2**).

We also analyzed results for participants who had not received their primary vaccination dose. Among those who had not been previously vaccinated (n=163), willingness to register for getting vaccinated was particularly high among the lottery arm. For the lottery arm(T4), 62.5 percent (n=30) of participants were willing to register for getting vaccinated. We also found statistically significant results for the lottery arm; the probability of willingness to register for the vaccine increased by 52.5 percentage points (CI: [0.34-0.70] p<0.01) (**Table 2**).

**Table 3** presents the regression results (OLS) for the primary outcome (willingness to register for getting vaccinated). Our results indicate that exposure to three out of four treatments, in comparison with the control group, led to an increase in the probability of willingness to get boosted. Of these three experimental conditions, the highest uptake was for individuals getting the *cash-prize lottery treatment*; the probability of willingness to register for getting boosted increased by 42 percentage points(CI: [0.359, 0.474]p<0.01). For participants who received the *vaccine mandates treatment* arm, the probability of willingness to register for getting boosted increased by 8 percentage points, (CI: [0.038, 0.121, p<0.01). For the side-effects minimization treatment arm, the probability of willingness to register for getting boosted increased by 6 percentage points (CI: [0.021, 0.101],p<0.01). **(see Annex Figure A1)** 

We included several variables in the regression model to understand the relationship between other covariates and the outcome variable. (see **Annex Table A3**). Education was a significant predictor of the willingness to register for getting vaccinated. Respondents who had completed intermediate (grade 12) or received higher education had higher probability of willingness to register for getting boosted as compared to respondents who had not received any education. The probability of willingness to register for getting boosted increased with the level of education. For instance, participants who had completed a Masters or professional degree had 29.7 percentage points higher probability of willingness to register for getting boosted(CI: [0.164, 0.429],p<0.01), while those who had completed grade 12 had 9.5 percentage points higher probability of willingness to register for getting boosted (CI: [0.035,

0.154]p<0.01). Age and income were also associated with the probability of willingness to register for getting boosted. An increase in respondent age was associated with lower probability of willingness to register for getting boosted (Coefficient: -0.002,p<0.05), while an increase in income was associated with higher probability of willingness to register for getting boosted (Coefficient: 0.150, p<0.01). Respondents who had gotten vaccinated against COVID-19 to protect themselves against the virus had higher probability of willingness to register for getting boosted (Coefficient: 0.054, p<0.05).

#### Follow-up survey results

The follow-up sample comprised 744 participants. Fifty-seven percent of respondents were males and 43 percent were females. The average age of the participants was 39 years.

For the first outcome variable, immediate vaccination (if the participant got vaccinated on the same day) a total of 1.36 percent respondents (n=10) reported getting vaccinated the same day. For the second outcome variable, subsequent vaccination (if the participant got vaccinated a few days later) 7 percent (n=51) respondents reported getting vaccinated. (See **Annex C Table A4**)

The outcome variable, immediate vaccination had insignificant result across all four treatments. However, the outcome variable subsequent vaccination had significant results for the lottery arm. The probability of getting the booster short was higher by 20 percentage points as compared to the control arm (CI: [0.130, 0.269], p<0.01). (see **Table 4**, Annex **Figure 2**)

#### **Discussion**

In this study, using a five-arm randomized control trial we examined the effect of behaviorally informed messages on willingness to get boosted, and eventual booster uptake. We found substantial effects on willingness to boost against COVID-19 in three of our four intervention arms. Of the four treatment conditions, the highest uptake was for individuals getting the *cash-prize lottery treatment*, the probability of willingness to

register for getting boosted increased by 42 percentage points(CI: [0.359, 0.474, p<0.01). For participants who received the *vaccine mandates treatment* arm, the probability of willingness to register for getting boosted increased by 8 percentage points,(CI: [0.038, 0.121], p<0.01). For the side-effects minimization treatment arm, the probability of willingness to register for getting boosted increased by 6 percentage points (CI: [0.021, 0.101], p<0.01).

In the follow up survey, the outcome variable *subsequent vaccination* (if the participant got vaccinated a few days later) had significant results for the lottery arm. The probability of getting the booster shot was higher by 20 percentage points as compared to the control arm (CI: [0.130, 0.269], p<0.01).

Previous research finds mixed results on the use of financial incentives for encouraging vaccine uptake (63) (64). Evidence suggests that guaranteed immediate payments can be more effective in encouraging behavior change as compared to lotteries and gimmicks (65). A randomized control trial in Sweden found that a modest monetary incentive led to an increase in vaccination rates, with monetary incentives having a higher impact on vaccination uptake than other behavioral nudges (66). However, guaranteed modest monetary incentives may not be very practical or cost-effective in low- and middle-income country, setting or as way to motivate booster behavior. Lotteries, by contrast, while requiring a larger incentive, have the potential to be feasible and cost-effective in LMICs. Lotteries have also been shown to be effective in certain circumstances and may be appropriate for one-off booster shots that do not require a second shot. A study conducted in the US using synthetic control methods examined the effects of lotteries on first dose and complete vaccination rates in eighteen states. The results showed that lotteries had a positive impact on first-dose vaccination rates in fifteen states. However, for complete vaccination, over half of the states analyzed exhibited null or negative effects (67). The results of our study are consistent with previous research that finds that monetary incentives can lead to an increase in vaccine uptake (68).

In terms of other treatments, we find significant effects of the *vaccine mandates* arm and *side-effects minimization* arm in terms of willingness to get vaccinated. Using mandates to move the population towards vaccination has been advocated as a social incentive to increase vaccination by some (69), while others advocate for less coercive policy instruments (70). Similarly, positive framing of the vaccine can encourage uptake. For instance, in a recent study authors found that providing information about the effectiveness and safety of the COVID-19 vaccine, and framing possible side effects as temporary led to increased vaccination confidence in the US (71). Our results are consistent with such studies.

However, our findings do not indicate that references to the quality of the vaccine and manufacturer (*vaccine manufacturer arm*) had an impact on its uptake. According to previous research, the acceptance of vaccines is influenced by the origin of the vaccine (39) (40) (41). In a study conducted in Brazil, it was observed that Brazilians were more inclined to reject vaccines developed in China and Russia when compared to those developed in the US or England (39). It is possible that the results of our study might be driven by diverse preferences for vaccines among Pakistani's. For instance, in an online questionnaire administered to people in Pakistan in January 2021 (N=2158 respondents), 43.3 percent expressed a preference for the Chinese vaccine (72). Similarly, a survey conducted in July 2021 revealed that 36 percent of the participants favored Sinopharm and Sinovac, while 35 percent preferred Pfizer (73).

Our findings also shed light on the difference between intention and behavior in terms of getting vaccinated. In the main survey, the lottery arm, the vaccine mandates arm, and the side effects minimization arm were all significant. Yet, in the follow up survey, when participants were asked if they got vaccinated on the same day, an insignificant number actually followed through to vaccination while at the hospital. While a larger share did report vaccinating a few days later, only the lottery arm had significant results. Moreover, most of the participants stated that they had gotten vaccinated at different clinic/hospital instead of the hospital where the survey was conducted. Previous research provides several explanations for such behavior. Sheeran and Orbell (1998) in a study on

condom use argue that there can be a gap in intention and behavior due to situational factors (e.g. people may not find a vaccination center close by to get vaccinated). In our follow-up survey, we found that most the participants who got vaccinated later went to a nearby clinic instead of the hospital. This suggests that convenience is of utmost importance to people. However, concerningly, only 4% of respondents in the control arm agreed to get boosted on spot suggesting fairly low demand for boosters even if they are made conveniently available. This finding suggests that messaging does make a difference beyond mere availability. Both the mandate and the risk minimization arm increased uptake compared with merely offering the vaccine. However, only the lottery arm substantially increased willingness to boost. Other factors discussed by Sheeran and Orbell (1998) include, memory failures (e.g. failure to remember to perform a task), attitudinal factors (e.g. a mismatch between positive intentions and negative attitudes), and social influence (e.g. an inability to follow through because of peer pressure) (80). Consequently, measures can be devised to narrow the gap between intention and behavior and can be the focus of future work(74).

#### **Limitations**

There are several limitations of our analysis. *First*, the study had envisioned a vaccination booth would be set up very close to the survey team in order to facilitate onspot vaccination. However, due to unforeseen logistical constraints at the hospital, the survey team was stationed at a different hospital wing from the vaccination site. We suspect the vaccination site being far away might have limited people's uptake. *Second*, the financial incentives we offered fostered high participation, but may themselves be considered a financial incentive constraining our ability to generalize from these findings.

## **Policy implications**

There are several policy implications stemming from this analysis. The magnitude of our results for the lottery arm suggest that the use of cash incentives may be a practical and cost-effective mechanism for many LMICs to increase booster uptake as we show that even a modest cash incentive increased uptake.

While our results lend support for the use of financial incentives, there are arguments both for and against the use of financial incentives as a policy tool to promote vaccination. Critics argue that such incentives make health seeking behavior conditional on getting payments, and may negatively impact the morals and the general tendency of the individuals towards meeting social obligations (75). Those in favor of monetary vaccination incentives consider such payments useful as they can potentially cut back on indirect costs (76) and can bring attention to the importance of achieving high vaccination rates (77). They can also foster social responsibility by rewarding good behavior (78). The incentive structure however needs to be designed appropriately to get effective results. In case of primary vaccinations, entry into the lottery should be allowed only after complete vaccination for encouraging compliance at each stage (79). In the case of booster vaccination, financial incentives can encourage uptake for people who have already shown willingness to get vaccinated by getting primary vaccine shots, but just need a nudge to get boosted (80).

Our study design also enabled us to compare across different behavioral strategies. Correcting miscalculation of the risk of side-effects compared with the risk complications from COVID-19 was also an effective strategy to increase booster uptake by 8 percentage points. Likewise, reminding people that they may need vaccines to engage in other activities they value such as travel or work was sufficient to increase vaccine/booster uptake by 6 percentage points. This supports the efficacy of mandates at compelling uptake, though notably lotteries were more effective, which are less coercive and require less enforcement.

#### Conclusion

We conclude that the use of cash incentives may be a practical way to increase voluntary booster uptake when vaccines are also made easily and freely available to the public seeking routine care. Financial incentives may lead to increased vaccination uptake without limiting individual's freedom as in the case with mandates (81), and may act as a catalyst for fostering social responsibility by rewarding good behavior (82). This is likely a cost-effective mechanism for many low- and- middle income countries to

increase booster uptake as we show that even a modest cash incentive increased uptake. However, the continued ability of countries to offer free vaccination through onsite vaccine clinics remains in question and may depend on global vaccine donation programs.

#### References

- World Health Organization. Interim statement on the use of additional booster doses of Emergency Use Listed mRNA vaccines against COVID-19. 2022 May 17. <a href="https://www.who.int/news/item/17-05-2022-interim-statement-on-the-use-of-additional-booster-doses-of-emergency-use-listed-mrna-vaccines-against-covid-19">https://www.who.int/news/item/17-05-2022-interim-statement-on-the-use-of-additional-booster-doses-of-emergency-use-listed-mrna-vaccines-against-covid-19</a>. Accessed on March 29, 2023.
- Government of the United States. COVID-19 Public Education Campaign.
   COVID-19 Vaccine Boosters for Those With Underlying Medical Conditions.
   <a href="https://wecandothis.hhs.gov/covid-19-vaccine-boosters-for-people-with-certain-medical-conditions">https://wecandothis.hhs.gov/covid-19-vaccine-boosters-for-people-with-certain-medical-conditions</a>. Accessed on April 13, 2023.
- 3. World Health Organization. 2022 May 17. <a href="https://www.who.int/news/item/17-05-2022-interim-statement-on-the-use-of-additional-booster-doses-of-emergency-use-listed-mrna-vaccines-against-covid-19">https://www.who.int/news/item/17-05-2022-interim-statement-on-the-use-of-additional-booster-doses-of-emergency-use-listed-mrna-vaccines-against-covid-19</a>. Accessed on March 29, 2023.
- Shah A, Coiado OC. COVID-19 vaccine and booster hesitation around the world:
   A literature review. Front Med. 2023 Jan 12; 9:1054557.
- Lai X, Zhu H, Wang J, Huang Y, Jing R, Lyu Y, Zhang H, Feng H, Guo J, Fang H. Public Perceptions and Acceptance of COVID-19 Booster Vaccination in China: A Cross-Sectional Study. Vaccines (Basel). 2021 Dec 10; 9(12), 1461.
- Abouzid M, Ahmed AA, El-Sherif DM, Alonazi WB, Eatmann AI, Alshehri MM, Saleh NR, Ahmed MH, Aziz IA, Abdelslam AE, Omran AA, Omar AA, Ghorab MA, Islam SMS. Attitudes toward Receiving COVID-19 Booster Dose in the Middle East and North Africa (MENA) Region: A Cross-Sectional Study of 3041 Fully Vaccinated Participants. Vaccines (Basel). 2022 Aug 6; 10(8), 1270.
- 7. Bennet NG, Bloom DE, Ferranna M. Factors underlying COVID-19 vaccine and booster hesitancy and refusal, and incentivizing vaccine adoption. PLoS One. 2022 Sep 2022; 17(9): e0274529.
- 8. Qin C, Yan W, Tao L, Liu M, Liu J. The Association between Risk Perception and Hesitancy toward the Booster Dose of COVID-19 Vaccine among People Aged 60 Years and Older in China. Vaccines (Basel). 2022 Jul 12; 10(7):1112.

- Motta M. The Correlates & Public Health Consequences of Prospective Vaccine
  Hesitancy among Individuals Who Received COVID-19 Vaccine Boosters in the
  U.S. Vaccines (Basel). 2022 Oct 25;10(11):1791.
- 10. Chrissian AA, Oyoyo UE, Patel P, Beeson WL, Loo LK, Tavakoli S, Dubov A. Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination. Vaccine. 2022 May 20; 40(23): 3174-3181.
- 11. Khan MSR, Nguyen TXT, Lal S, Watanapongvanich S, Kadoya Y. Hesitancy towards the Third Dose of COVID-19 Vaccine among the Younger Generation in Japan. Int J Environ Res Public Health. 2022 Jun 8; 19(12): 7041.
- 12. Ghazy R M, Abdou M S, Awaidy S, Sallam M, Elbarazi I, Youssef N, Fiidow O A, Mehdad S, Hussein M F, Adam M F, Abdullah F S A, Rebai W K, Raad E B, Hussein M, Shehata S F, Ismail I I, Salam A A, Samhouri D. Acceptance of COVID-19 Vaccine Booster Doses Using the Health Belief Model: A Cross-Sectional Study in Low-Middle- and High-Income Countries of the East Mediterranean Region. Int J Environ Res Public Health. 2022 Sep 25; 19, 12136.
- 13. Babicki M, Mastalerz-Migas A. Attitudes of Poles towards the COVID-19 Vaccine Booster Dose: An Online Survey in Poland. Vaccines (Basel). 2022 Jan 2; 10(1):68.
- 14. Al-Qerem W, Jarab A, Hammad A, Alsajri AH, Al-Hishma SW, Ling J, Alabdullah AS, Salama A, Mosleh R. Knowledge, Attitudes, and Practices of Adult Iraqi Population Towards COVID-19 Booster Dose: A Cross-Sectional Study. Patient Prefer Adher. 2022 Jun 23; 16: 1525-1537.
- 15. Shah A, Coiado OC. COVID-19 vaccine and booster hesitation around the world: A literature review. Front Med. 2023 Jan 12; 9:1054557.
- 16. Matenga TFL, Zulu JM, Davis LM, Chavula MP. Motivating factors for and barriers to the COVID-19 vaccine uptake: A review of social media data in Zambia. Cogent Public Health. 2022 Apr 20; 9: 2059201.
- 17. Karaivanov A, Kim D, Lu SE, Shigeoka H. COVID-19 vaccination mandates and vaccine uptake. Nat. Hum. Behav. 2022 Jun 2; 6:1615–1624.

- 18. Mills MC, Ruttenauer T. The effect of mandatory COVID-19 certificates on vaccine uptake: synthetic-control modelling of six countries. Lancet Public Health. 2021 Dec 13; 7: e15-22.
- 19. Drew L. Did COVID vaccine mandates work? What the data say. Nature. 2022 Jul 13; 607, 22-25.
- 20. Kreps SE, Kriner DL. How do COVID-19 vaccine mandates affect attitudes toward the vaccine and participation in mandate-affected activities? Evidence from the United States. Vaccine. 2022 Dec 5;40(51):7460-7465.
- 21. Brennan J. A libertarian case for mandatory vaccination. J Med Ethics. 2018 Jan; 44 (1): 37–43.
- 22. World Health Organization. SAGE updates COVID-19 vaccination guidance. 2023 Mar 28. Available at: <a href="https://www.who.int/news/item/28-03-2023-sage-updates-covid-19-vaccination-guidance">https://www.who.int/news/item/28-03-2023-sage-updates-covid-19-vaccination-guidance</a>. Accessed on May 19, 2023.
- 23. Schreiber M. 'People aren't taking this seriously': experts say US COVID surge is big risk. The Guardian. 2023 Jan 15. Available at:

  <a href="https://www.theguardian.com/world/2023/jan/15/covid-19-coronavirus-us-surge-complacency">https://www.theguardian.com/world/2023/jan/15/covid-19-coronavirus-us-surge-complacency</a>
- 24. Dubov A, Phung C. Nudges or mandates? The ethics of mandatory flu vaccination. Vaccine. 2015 May 21; 33 (22): 2530–2535.
- 25. Campbell JV, Garfein RS, Thiede H, Hagan H, Ouellet LJ, Golub ET, Hudson SM, Ompad DC, Weinbaum C, <u>DUIT Study Team</u>. Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users. 2007 Nov; 91, S64-72.
- 26. Chapman GB, Li M, Colby H, Yoon H. Opting in vs opting out of influenza vaccination. JAMA. 2010 Jul 07; 304(1):43–44.
- 27. Johnson EJ, Goldstein DG. Medicine. Do defaults save lives? *Science*. 2003 Dec ;302(5649):1338–1339.
- 28. Reiter PL, McRee AL, Pepper JK, Brewer NT. Default Policies and Parents' Consent for School-Located HPV vaccination. J Behav Med. 2012 Dec; 35(6): 651–657.

- 29. Sudharsanan N, Favaretti C, Hachaturyan V, Barnighausen T, Vandormael A. Effects of side-effect risk framing strategies on COVID-19 vaccine intentions: a randomized controlled trial. elife. 2022 Aug 16;11: e78765.
- 30. Barnes K, Faasse K, Colagiuri B. The impact of side effect framing on COVID-19 booster vaccine intentions in an Australian sample. Vaccine. 2023 March 17; 41(12): 2046-2054.
- 31. Motta M, Sylvester S, Callaghan T, Lunz-Trujillo K. Encouraging COVID-19

  Vaccine Uptake Through Effective Health Communication. Front. Polit. Sci. 2021

  Jan 28; 3:630133.
- 32. Palm R, Bolsen T, Kingsland JT. The Effect of Frames on COVID-19 Vaccine Resistance. Front. Polit. Sci. 2021 May 13. 3:661257.
- 33. Davis CJ, Golding M, McKay R. Efficacy information influences intention to take COVID-19 vaccine. Br. J. Health Psychol. 2021 Jul 11; 27(2): 300-319.
- 34. Ashworth M, Thunstrom L, Cherry TL, Finnoff DC. Emphasize personal health benefits to boost COVID-19 vaccination rates. PNAS. 2021 Jul 27; 118(32): e2108225118.
- 35. Barnes K, Colagiuri B. Positive Attribute Framing Increases COVID-19 Booster Vaccine Intention for Unfamiliar Vaccines. Vaccines (Basel). 2022 Jun; 10(6):962.
- 36. Sunstein CR. Probability neglect: Emotions, Worst cases, and Law. Yale L. J. 2002; 112(1), 61-107.
- 37. Ryalat S, Alduraidi H, Al-Ryalat SA, Alzu'bi M, Alzyoud M, Odeh N, Alrawabdeh J. Attitudes towards COVID-19 Booster Vaccines, Vaccine Preferences, Child Immunization, and Recent Issues in Vaccination among University Students in Jordan. Vaccines (Basel). 2022 Aug 4;10(8):1258.
- 38. Hossain MB, Alam MZ, Islam MS, Sultan S, Faysal MM, Rima S, Hossain MA, Al-Mamun A. COVID-19 vaccine hesitancy among the adult population in Bangladesh: A nationwide cross-sectional survey. PLOS ONE. 2021 Dec 9; 16(12): e0260821.

- 39. Lazarus JV, Wyka K, White TM, Picchio CA, Rabin K, Ratzan SC, Leigh JP, Hu J, El-Mohandes A. Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021. Nat. Commun. 2022 Jul 01; 13, 3801.
- 40. Wong LP, Alias H, Danaee M, Ahmed J, Lachyan A, Cai CZ, Lin Y, Hu Z, Tan SY, Lu Y, Cai G, Nguyen DK, Seheli FN, Alhammadi F, Madhale MD, Atapattu M, Quazi-Bodhanya T, Mohajer S, Zimet GD, Zhao Q. COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries. Infect Dis Poverty. 2021 Oct 07; 10(1):122.
- 41. Dror AA, Daoud A, Morozov NG, Layous E, Eisenbach N, Mizrachi M, Rayan D, Bader A, Francis S, Kaykov E, Barhoum M, Sela E. Vaccine hesitancy due to vaccine country of origin, vaccine technology, and certification. Eur J Epidemiol. 2021 Jul; 36(7), 709-714.
- 42. Halpern SD, French B, Small DS, Saulsgiver K, Harhay MO, Audrain-McGovern J, Loewenstein G, Brennan TA, Asch DA, Volpp KG. Randomized Trial of Four Financial-Incentive Programs for Smoking Cessation. *N Engl J Med.* 2015 May 28; 372: 2108-2117.
- 43. Barber A, West J. Conditional cash lotteries increase COVID-19 vaccination rates. J Health Econ. 2022 Jan; 81:102578.
- 44. Chetty-Makhan, CM, Thirumurthy H, Bair EF, Bokolo S, Day C, Wapenaar K, Werner J, Long L, Maughan-Brown B, Miot J, Pascoe SJS, Buttenheim AM. Quasi-experimental evaluation of a financial incentive for first-dose COVID-19 vaccination among adults aged ≥ 60 years in South Africa. BMJ Glob. Health. 2022 Dec 06;7(12): e009625.
- 45. Kuznetsova L, Diago-Navarro E, Mathu R, Trilla, A. Effectiveness of COVID-19 Vaccination Mandates and Incentives in Europe. Vaccines. 2022 Oct 14;10(10):1714.
- 46. Fuller S, Kazemian S, Algara C. Simmons DJ. Assessing the effectiveness of COVID-19 vaccine lotteries: A cross-state synthetic control methods approach. PLoS ONE. 2022 Sep 28. 17(9): e0274374.

- 47. Sprengholz P, Henkel L, Betsch C. Payments and freedoms: Effects of monetary and legal incentives on COVID-19 vaccination intentions in Germany. PLoS One. 2022 May 24;17(5): e0268911.
- 48. Thirumurthy H, Milkman KL, Volpp KG, Buttenheim AM, Pope DG. Association between statewide financial incentive programs and COVID-19 vaccination rates. PLoS One. 2022 Mar 30; 17(3): e0263425.
- 49. Barber A, West J. Conditional cash lotteries increase COVID-19 vaccination rates. J Health Econ. 2022 Jan; 81: 102578.
- 50. Campos-Mercade P, Meier AN, Schneider FH, Meier S, Pope D, Wengstrom E. Monetary incentives increase COVID-19 vaccinations. Sci. 2021 Nov 12; 374(6569): 879-882.
- 51. Jacobson M, Chang TY, Shah M, Pramanik R, Shah SB. Can financial incentives and other nudges increase COVID-19 vaccination among the vaccine hesitant? A randomized trial. Vaccine. 2022 Oct 12; 40(43):6235-6242.
- 52. Mallow PJ, Enis A, Wackler M, Hooker EA. COVID-19 financial lottery effect on vaccine hesitant areas: Results from Ohio's Vax-a-million program. Am J Emerg Med. 2022 Jun; 56, 316-317.
- 53. Acharya B, Dhakal C. Implementation of State Vaccine Incentive Lottery Programs and Uptake of COVID-19 Vaccinations in the United States. JAMA Netw. Open. 2021 Dec 9; 4(12): e2138238.
- 54. Neil KR, Sehgal BA. Impact of Vax-a-Million Lottery on COVID-19 Vaccination Rates in Ohio. Am J Med. 2021 Nov;134(11), 1424-1426.
- 55. Hing NYL, Woon, YL, Lee YK, Kim HJ, Lothfi NM, Wong E, Perialathan K., Sanusi NHA, Isa A, Leong CT, Costa-Font J. When do persuasive messages on vaccine safety steer COVID-19 vaccine acceptance and recommendations? Behavioural insights from a randomised controlled experiment in Malaysia. BMJ Glob. Health. 2022 Jun 21; 7: e009250. doi:10.1136/bmjgh-2022-009250.
- 56. Ali I, Shah SA, Siddiqui. Pakistan confirms first two cases of coronavirus, govt says 'no need to panic'. DAWN. 2020 Feb 26. Available at: https://www.dawn.com/news/1536792.

- 57. Riaz S. Rights activists raise alarm as Pakistani provinces call for punitive measures against the unvaccinated. Arab News. 2021 Jun 16. Available at: <a href="https://www.arabnews.pk/node/1877541/pakistan">https://www.arabnews.pk/node/1877541/pakistan</a>
- 58. Mehmood F, Haris IB. More carrot, less stick: the constitutional limits of Pakistan's vaccination drive. Lex-Atlas: Covid-19. Available at: <a href="https://lexatlas-c19.org/more-carrot-less-stick-the-constitutional-limits-of-pakistans-vaccination-drive/">https://lexatlas-c19.org/more-carrot-less-stick-the-constitutional-limits-of-pakistans-vaccination-drive/</a>
- 59. Shahzad A. Pakistan demands proof of vaccine for school, restaurant, transport staff. Reuters. 2021 Jul 29. Available at: <a href="https://www.reuters.com/world/china/pakistan-ban-public-sector-education-malls-air-travel-unvaccinated-2021-07-29/">https://www.reuters.com/world/china/pakistan-ban-public-sector-education-malls-air-travel-unvaccinated-2021-07-29/</a>
- 60. Junaidi I. Unvaccinated people banned from domestic air travel. DAWN. 2023 May 05. Available at: https://www.dawn.com/news/1636795
- 61. Jamal S. Pakistan to rollout COVID-19 booster shots for people 30 and above. World Asia, Pakistan. 2021 Dec 21. Available at:

  <a href="https://gulfnews.com/world/asia/pakistan/pakistan-to-rollout-covid-19-booster-shots-for-people-30-and-above-1.84543991">https://gulfnews.com/world/asia/pakistan/pakistan-to-rollout-covid-19-booster-shots-for-people-30-and-above-1.84543991</a>
- 62. COVID-19 Global Tracker. (nd) Available at: https://www.covid19globaltracker.org/#vaccination. Accessed on May 11, 2023.
- 63. Fuller S, Kazemian S, Algara C. Simmons DJ. Assessing the effectiveness of COVID-19 vaccine lotteries: A cross-state synthetic control methods approach. PLoS ONE. 2022 Sep 28. 17(9): e0274374.
- 64. Sprengholz P, Henkel L, Betsch C. Payments and freedoms: Effects of monetary and legal incentives on COVID-19 vaccination intentions in Germany. PLoS One. 2022 May 24;17(5): e0268911.
- 65. Editorial. Vaccine incentives do not backfire policymakers take note. Nature. 2023 Jan 11;613:215. Available from: https://doi.org/10.1038/d41586-023-00018-z
- 66. Campos-Mercade P, Meier AN, Schneider FH, Meier S, Pope D, Wengstrom E. Monetary incentives increase COVID-19 vaccinations. Sci. 2021 Nov 12; 374(6569): 879-882.

- 67. Fuller S, Kazemian S, Algara C, Simmons DJ. Assessing the effectiveness of COVID-19 vaccine lotteries: A cross-state synthetic control methods approach. PLoS ONE. 2022 Sep 28. 17(9): e0274374
- 68. Khazanov GK, Stewart R, Pieri MF, Huang C, Robertson CT, Schaefer KA, Ko H, Fishman J. The effectiveness of financial incentives for COVID-19 vaccination: A systematic review. Prev Med. 2023 May 6; 172:107538.
- 69. Volpp KG, Cannuscio CC. Incentives for immunity Strategies for increasing COVID-19 uptake. N Engl J Med. 2021 Jul 01.
- 70. World Health Organization. COVID-19 and mandatory vaccination: ethical considerations: policy brief. 2022 May 30.
- 71. Latkin CA, Dayton L, Yi G, Konstantopoulos A, Boodram B. Trust in a COVID-19 vaccine in the U.S.: A social-ecological perspective. Soc Sci Med. 2021 Feb; 270: 113684.
- 72. Arshad, M. S., Hussain, I., Mahmood, T., Hayat, K., Majeed, A., Imran, I., Saeed, H., Iqbal, M. O., Uzair, M., Rehman, A. U., Ashraf, W., Usman, A., Syed, S. K., Akbar, M., Chaudhry, M. O., Ramzan, B., Islam, M., Saleem, M. U., Shakeel, W., Iqbal, I., ... Rasool, M. F. (2021). A National Survey to Assess the COVID-19 Vaccine-Related Conspiracy Beliefs, Acceptability, Preference, and Willingness to Pay among the General Population of Pakistan. *Vaccines*, 9(7), 720. https://doi.org/10.3390/vaccines9070720
- 73. Khattak S, Idrees M, Iqbal HI, et al. Assessment of Attitudes and Intentions towards COVID-19 Vaccines and Associated Factors among General Populations of Pakistan: A Cross-Sectional Study. *Vaccines* 2022; 10: 1583.
- 74. Sheeran P, Orbell S. Why do intentions predict condom use behavior? A theoretical analysis. Psychol Health. 1998; 13(4), 651-669.
- 75. Largent EA. Miller FG. Problems with paying people to be vaccinated against COVID-19. JAMA. 2021. 325(6), 534–535.
- 76. Volpp KG, Cannuscio CC. Incentives for immunity Strategies for increasing COVID-19 uptake. N Engl J Med. 2021 Jul 01.

- 77. McLaren ZM. Everyone Wins: Vaccine Lotteries Can Cost-Effectively Increase COVID-19 Booster Vaccination Rates. Am J Epidemiol. 2023 Jan 13; 192(4): 510–513.
- 78. Jecker NS. Cash incentives, ethics, and COVID-19 vaccination. Sci. 2021 Nov 11; 374 (6569):819-820.
- 79. Fuller S, Kazemian S, Algara C, Simmons DJ. Assessing the effectiveness of COVID-19 vaccine lotteries: A cross-state synthetic control methods approach. PLoS ONE. 2022 Sep 28. PLoS One. 17(9): e0274374.
- 80. McLaren ZM. Everyone Wins: Vaccine Lotteries Can Cost-Effectively Increase COVID-19 Booster Vaccination Rates. Am J Epidemiol. 2023 Jan 13; 192(4): 510–513.
- 81. Savulescu J, Pugh J, Wilkinson D. Balancing incentives and disincentives for vaccination in a pandemic. Nat. Med. 2021 Sep 06; 27:1500-1503.
- 82. Jecker NS. Cash incentives, ethics, and COVID-19 vaccination. Sci. 2021 Nov 11; 374 (6569), 819-820.

#### **Tables and Figures**

Exhibit 1: Figure 1: Trial Profile

Exhibit 2: Table 1: Descriptive statistics

Exhibit 3: Table 2: Respondents consenting to register for getting the booster/vaccine shot by treatment


group

**Exhibit 4:** Table 3: OLS regression model showing relationship between treatment arms and willingness

to register for getting vaccinated

**Exhibit 5:** Table 4: Follow up survey - OLS regression model showing relationship between treatment arms and vaccination status: (i) Got vaccinated the same day (ii) Got vaccinated many days later

Figure 1: Trial Profile



**Table 1: Descriptive statistics** 

|     | Total      | Control | T1      | T2      | T3      | T4      |
|-----|------------|---------|---------|---------|---------|---------|
|     | (n= 1,564) | (n=298) | (n=318) | (n=306) | (n=309) | (n=333) |
| Age | 42.43      | 42.48   | 41.98   | 43.07   | 43.05   | 41.65   |
|     | (11.66)    | (12.01) | (10.83) | (12.02) | (11.64) | (11.79) |

| Gender                                            |            |               |               |               |               |               |
|---------------------------------------------------|------------|---------------|---------------|---------------|---------------|---------------|
| Female                                            | 921        | 171           | 206           | 174           | 184           | 186           |
|                                                   | (58.89%)   | (57.38%)      | (64.78%)      | (56.86%)      | (59.55%)      | (55.86%)      |
| Male                                              | 639        | 126           | 110           | 131           | 125           | 147           |
|                                                   | (40.86%)   | (42.28%)      | (34.59%)      | (42.81%)      | (40.45%)      | (44.14%)      |
| Transgender                                       | 4          | 1             | 2             | 1             | ,             | ,             |
| · ·                                               | (0.26%)    | (0.34%)       | (0.63%)       | (0.33%)       |               |               |
|                                                   |            |               |               |               |               |               |
| Highest level of                                  |            |               |               |               |               |               |
| education                                         |            |               |               |               |               |               |
| Madrassah                                         | 147        | 32            | 28            | 31            | 20            | 36            |
|                                                   | (9.46%)    | (10.81%)      | (8.89%)       | (10.16%)      | (6.49%)       | (10.91%)      |
| Did not go to school                              | 324        | 69            | 75            | 61            | 73            | 46            |
|                                                   | (20.85%)   | (23.31%)      | (23.81%)      | (20.00%)      | (23.70%)      | (13.94%)      |
| Dropped out before matric                         | 228        | 40            | 49            | 47            | 52            | 40            |
|                                                   | (14.67%)   | (13.51%)      | (15.56%)      | (15.41%)      | (16.88%)      | (12.12%)      |
| Matric                                            | 425        | 69            | 96            | 99            | 82            | 79            |
|                                                   | (27.35%)   | (23.31%)      | (30.48%)      | (32.46%)      | (26.62%)      | (23.94%)      |
| Intermediate/F.A./F.Sc.                           | 256        | 63            | 42            | 41            | 52            | 58            |
|                                                   | (16.47%)   | (21.28%)      | (13.33%)      | (13.44%)      | (16.88%)      | (17.58%)      |
| Bachelors                                         | 119        | 21            | 20            | 20            | 26            | 32            |
|                                                   | (7.66%)    | (7.09%)       | (6.35%)       | (6.56%)       | (8.44%)       | (9.70%)       |
| Masters/MPhil                                     | ` 45 ´     | 2             | 4             | 3             | 3             | 33            |
|                                                   | (2.90%)    | (0.68%)       | (1.27%)       | (0.98%)       | (0.97%)       | (10.00%)      |
| M.B.B.S./L.L.B.                                   | ` 10 ´     | ,             | ` 1 ´         | ` 3 ´         | ,             | ` 6           |
|                                                   | (0.64%)    |               | (0.32%)       | (0.98%)       |               | (1.82%)       |
|                                                   | ,          |               | , ,           | ,             |               | ,             |
| Monthly household                                 | 34,368     | 33,104        | 33,576        | 33,298        | 34,410        | 37,164        |
| income                                            | (12540.16) | (10610.38)    | (9359.84)     | (11883.17)    | (14307.91)    | (15027.41)    |
|                                                   |            |               |               |               |               |               |
| Why did you get                                   |            |               |               |               |               |               |
| vaccinated the first                              |            |               |               |               |               |               |
| time?*                                            |            |               |               |               |               |               |
| To protect against COVID                          | 807        | 153           | 169           | 152           | 184           | 149           |
| 19                                                | (57.60%)   | (57.09%)      | (59.51%)      | (55.07%)      | (63.89%)      | (52.28%)      |
| Because I was required to                         | 381        | 69            | 76            | 70            | 81            | 85            |
| in order to go out/attend                         | (27.19%)   | (25.75%)      | (26.76%)      | (25.36%)      | (28.13%)      | (29.82%)      |
| school/ or work                                   |            |               |               |               |               |               |
| To protect others                                 | 271        | 47            | 49            | 46            | 65            | 64            |
|                                                   | (19.34%)   | (17.54%)      | (17.25%)      | (16.67%)      | (22.57%)      | (22.46%)      |
| Everyone I knew was                               | 160        | 28            | 33            | 28            | 30            | 41            |
| vaccinating                                       | (11.42%)   | (10.45%)      | (11.62%)      | (10.14%)      | (10.42%)      | (14.39%)      |
|                                                   | ( , . ,    |               |               |               |               | 40            |
| My doctor told me to do it                        | 90         | 20            | 16            | 24            | 11            | 19            |
| My doctor told me to do it                        | ,          | 20<br>(7.46%) | 16<br>(5.63%) | 24<br>(8.70%) | 11<br>(3.82%) | 19<br>(6.67%) |
| My doctor told me to do it  Due to travel reasons | 90         |               |               |               |               |               |

# Vaccinated against

# **COVID -19**

| Yes                                     | 1,401    | 268      | 284      | 276      | 288      | 285      |
|-----------------------------------------|----------|----------|----------|----------|----------|----------|
|                                         | (89.58%) | (89.93%) | (89.31%) | (90.20%) | (93.20%) | (85.59%) |
| No                                      | 163      | 30       | 34       | 30       | 21       | 48       |
|                                         | (10.42%) | (10.07%) | (10.69%) | (9.80%)  | (6.80%)  | (14.41%) |
| Why have not you gotten vaccinated? * * |          |          |          |          |          |          |
| Concern about side                      | 114      | 22       | 28       | 20       | 12       | 32       |
| effects                                 | (69.94%) | (73.33%) | (82.35%) | (66.67%) | (57.14%) | (66.67%) |
| Do not trust the vaccines               | 109      | 19       | 22       | 15       | 14       | 39       |
|                                         | (66.87%) | (63.33%) | (64.71%) | (50%)    | (66.67%) | (81.25%) |
| Was not able to get the                 | 10       | 2        | 1        | 1        | 1        | 5        |
| shot                                    | (6.13%)  | (6.67%)  | (2.94%)  | (3.33%)  | (4.76%)  | (10.42%) |
| Did not have time                       | 1        |          |          |          |          | 1        |
|                                         | (0.61%)  |          |          |          |          | (2.08%)  |
| Disease not that bad                    | 2        |          |          | 1        | 1        |          |
|                                         | (1.23%)  |          |          | (3.33%)  | (4.76%)  |          |
| Against religious beliefs               |          |          |          |          |          |          |
| Other reasons                           | 10       | 3        | 1        | 4        | 2        |          |
|                                         | (6.13%)  | (10%)    | (2.94%)  | (13.33%) | (9.52%)  |          |

Data are mean (SD), or n (%).

Table 2: Respondents consenting to register for getting the booster/vaccine shot by treatment group

| Control<br>(n=298)<br>11 | T1<br>(n=318)<br>37 | T2<br>(n=306)                | T3<br>(n=309)                                                                              | T4                                                                                                                       |
|--------------------------|---------------------|------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| ,                        | ,                   | (n=306)                      | (n=309)                                                                                    | (m 222)                                                                                                                  |
| 11                       | 27                  |                              | ( 300)                                                                                     | (n=333)                                                                                                                  |
|                          | 31                  | 30                           | 19                                                                                         | 151                                                                                                                      |
| (3.69%)                  | (11.64%)            | (9.80%)                      | (6.15%)                                                                                    | (45.35%)                                                                                                                 |
|                          |                     |                              |                                                                                            |                                                                                                                          |
| iously not vacci         | nated consenting    | to register for              | getting the vac                                                                            | cine shot by                                                                                                             |
|                          |                     |                              |                                                                                            |                                                                                                                          |
| Control                  | T1                  | T2                           | T3                                                                                         | T4                                                                                                                       |
| (n=30)                   | (n=34)              | (n=30)                       | (n=21)                                                                                     | (n=48)                                                                                                                   |
| 3                        | 3                   | 2                            | 2                                                                                          | 30                                                                                                                       |
| (10%)                    | (8.8%)              | (6.6%)                       | (9.5%)                                                                                     | (62.5%)                                                                                                                  |
|                          | Control (n=30) 3    | Control T1 (n=30) (n=34) 3 3 | iously not vaccinated consenting to register for  Control T1 T2 (n=30) (n=34) (n=30) 3 3 2 | iously not vaccinated consenting to register for getting the vac  Control T1 T2 T3  (n=30) (n=34) (n=30) (n=21)  3 3 2 2 |

<sup>\*</sup> For a multi-select response questions, the percentage total can exceed 100%. \*\*Only those who had not gotten vaccinated were asked their reasons to do so.

## the booster shot

Note: Data are n (%). **T1** (Vaccine Mandates), **T2** (Side-effects minimization, **T3** (Manufacturer of the vaccine), **T4** (Lottery).

Table 3: OLS regression model showing relationship between treatment arms and willingness to register for getting vaccinated

|                                  | Willingness to register for getting<br>vaccinated |
|----------------------------------|---------------------------------------------------|
| T1 (Vaccine Mandates)            | 0.079***                                          |
|                                  | (0.021)                                           |
|                                  | [0.038, 0.121]                                    |
| T2 (Side-effects minimization)   | 0.061***                                          |
|                                  | (0.020)                                           |
|                                  | [0.021, 0.101]                                    |
| T3 (Manufacturer of the vaccine) | 0.025                                             |
|                                  | (0.018)                                           |
|                                  | [-0.010, 0.059]                                   |
| T4 (Lottery)                     | 0.417***                                          |
|                                  | (0.029)                                           |
|                                  | [0.359, 0.474]                                    |
| Constant                         | 0.037***                                          |
|                                  | (0.011)                                           |
|                                  | [0.015, 0.058]                                    |
| Observations                     | 1564                                              |

Robust

standard errors in parentheses and 95% confidence intervals in square brackets. \* p<0.1, \*\* p<0.05, \*\*\* p<0.01.

Table 4: Follow up survey - OLS regression model showing relationship between treatment arms and vaccination status: (i) Got vaccinated the same day (ii) Got vaccinated many days later

|                                  | Got vaccinated the same day | Got vaccinated many days later |
|----------------------------------|-----------------------------|--------------------------------|
|                                  | OLS                         | OLS                            |
| Treatments                       |                             |                                |
| T1 (Vaccine Mandates)            | -0.015                      | 0.028                          |
|                                  | (0.015)                     | (0.023)                        |
|                                  | [-0.0434141, 0.0135821]     | [-0.0165282, 0.0728647]        |
| T2 (Side-effects minimization    | -0.007                      | -0.015                         |
|                                  | (0.017)                     | (0.015)                        |
|                                  | [-0.0393507, 0.0260023]     | [-0.044384, 0.0150193]         |
| T3 (Manufacturer of the vaccine) | -0.010                      | 0.002                          |
| ,                                | (0.015)                     | (0.018)                        |
|                                  | [-0.0398404, 0.0204141]     | [ -0.0326954, 0.0375826]       |
| T4 (Lottery)                     | -0.010                      | 0.200***                       |
|                                  | (0.015)                     | (0.035)                        |
|                                  | [ -0.0398907, 0.0200155]    | [0.1304951, 0.2688366]         |
| Constant                         | 0.022*                      | 0.023*                         |
|                                  | (0.013)                     | (0.013)                        |
|                                  | [-0.0027517, 0.0468693]     | [ -0.0028096, 0.0479224]       |
| Observations                     | 733                         | 720                            |

Robust standard errors in parentheses and 95% confidence intervals in square brackets. \* p<0.1, \*\* p<0.05, \*\*\* p<0.01.

#### **Annexure**

#### **Annex A: Treatments**

#### **Treatment 1:**

Today we are offering a free COVID-19 vaccination clinic right here in the hospital. You can get the COVID-19 vaccine or booster. Vaccination and boosters may be required for certain travel destinations, work requirements or other types of activities. You just have to walk over to a room and they

will help register you and administer the shot on spot at no cost. Even if you have already been boosted or vaccinated they can check if you are eligible for another dose. Can I sign you up to get a COVID-19 vaccine or booster during your visit today?

#### **Treatment 2:**

Today we are offering a free COVID-19 vaccination clinic right here in the hospital. You just have to walk over to a room and they will help register you and administer the shot on spot at no cost. You can get the COVID-19 vaccine or booster. The vaccines and boosters are really safe. The overwhelming majority of people experience no side effects and can go about their day as usual. At worst, you might get a mild fever that will be over in a day or two, whereas getting COVID-19 can result in a long hospital stay or death. Elderly people are especially at risk of severe COVID-19 if they have not been boosted and the vaccines are safe for elderly people as well. Even if you have already been boosted or vaccinated they can check if you are eligible for another dose. Can I sign you up to get a COVID-19 vaccine or booster during your visit today?

#### **Treatment 3:**

Today we are offering a free COVID-19 vaccination clinic right here in the hospital. It is really easy to get vaccinated against COVID-19. You just have to walk over to a room and they will help register you and administer the shot on spot at no cost. You can get the COVID-19 vaccine or booster. The vaccines and booster shots being given today are all Pfizer or Moderna versions not the Chinese or Russian vaccines that were primarily available before. Even if you have already been boosted or vaccinated they can check if you are eligible for another dose. Can I sign you up to the COVID-19 vaccine or booster during your visit today?

#### **Treatment 4:**

Today we are offering a free COVID-19 vaccination clinic right here in the hospital. You just have to walk over to a room and they will help register you and administer the shot on spot at no cost. You can get the COVID-19 vaccine or booster. Even if you have already been boosted or vaccinated they can check if you are eligible for another dose. If you agree to get the vaccine your name will be entered in a lottery, a chance to win PKR 30,000. Can I sign you up to get the COVID-19 vaccine or booster during your visit today?

#### **Control group:**

Can I sign you up to get the COVID-19 vaccine or booster during your visit today?

#### Appendix B

#### **Uptake Survey**

| Field                | Question     | Answer |
|----------------------|--------------|--------|
| enum_name (required) | Conducted By |        |

| enum_other (required)                | Please specify other                                  |     |                           |
|--------------------------------------|-------------------------------------------------------|-----|---------------------------|
| resp_id (required)                   | Respondent ID                                         |     |                           |
| screener_1 (required)                | Hello, we are doing a survey                          | 1   | Yes                       |
|                                      | today- can I ask you a quick                          |     | No                        |
|                                      | question to determine if you                          | 2   | 110                       |
|                                      | are eligible?                                         |     |                           |
| screener_2 (required)                | Have you received a COVID-                            | 1   | Yes                       |
|                                      | 19 booster vaccine? In other                          | 2   | No                        |
|                                      | words, have you completed                             |     |                           |
|                                      | the booster shots?                                    |     |                           |
| screener_note                        | Thank you for your time. We                           |     |                           |
|                                      | are only speaking with people today who have not      |     |                           |
|                                      | received a booster shot.                              |     |                           |
| consent (required)                   | Hello, we are surveying                               |     |                           |
| consent (required)                   | people today about their                              |     |                           |
|                                      | experience getting the                                |     |                           |
|                                      | COVID-19 vaccine. It will just                        |     |                           |
|                                      | take a few minutes of your                            |     |                           |
|                                      | time. Moreover, for giving us                         |     |                           |
|                                      | your precious time and to                             |     |                           |
|                                      | respond to our questions, we                          |     |                           |
|                                      | will give you PKR 100 as a                            |     |                           |
|                                      | participation fee. You will                           |     |                           |
|                                      | receive the amount within 24-                         |     |                           |
|                                      | 48 hours.                                             |     |                           |
|                                      | Are you willing to participate?                       |     |                           |
|                                      | Refusing to not participate will not have any         |     |                           |
|                                      | consequences for you.                                 |     |                           |
| Survey                               | consequences for you.                                 |     |                           |
| survey > section 1                   |                                                       |     |                           |
| s1 q1 (required)                     | Gender of the respondent                              | 1   | Male                      |
|                                      | Enumerator to record                                  | 2   | Female                    |
|                                      |                                                       | 3   | Transgender               |
| of a2 (required)                     | What is your ourrest ago?                             | 3   | Transgender               |
| s1_q2 (required)<br>s1_q3 (required) | What is your current age? What is your mother tongue? | 1   | Urdu                      |
| 31_qo (requireu)                     | viriat is your mother tongue?                         | 2   | Punjabi                   |
|                                      |                                                       | 3   | Sindhi                    |
|                                      |                                                       | 4   | Pushto                    |
|                                      |                                                       | 5   | Balochi                   |
|                                      |                                                       | 6   | Siraiki                   |
|                                      |                                                       | 777 | Other                     |
| s1_q3_o (required)                   | Please specify other                                  |     | 1                         |
| s1_q4 (required)                     | What is the highest level of                          | 1   | Did not go to school      |
|                                      | education completed by the                            | 2   | Dropped out before matric |
|                                      | respondent?                                           | 3   | Matric                    |
|                                      |                                                       | 4   | Intermediate/F.A./F.Sc.   |
|                                      |                                                       | 6   | Bachelors                 |
|                                      |                                                       | 7   | Masters/MPhil             |
|                                      |                                                       |     |                           |
|                                      |                                                       | 8   | MBBS/LLB                  |

|                            |                                                        | 5   | Diploma Holder/Vocational                                       |
|----------------------------|--------------------------------------------------------|-----|-----------------------------------------------------------------|
|                            |                                                        | 0   | Training Madrassah                                              |
|                            |                                                        | 888 | Do not know                                                     |
|                            |                                                        | 999 | Refused to answer                                               |
| s1_q5 (required)           | What is the monthly income                             | 333 | Relused to allswel                                              |
| 31_q5 (required)           | of the household?                                      |     |                                                                 |
| s1_q5_n (required)         | Are you here for COVID-19                              | 1   | Yes                                                             |
|                            | related treatment?                                     | 2   | No                                                              |
| s1_q5_n_1 (required)       | Have you had COVID-19?                                 | 1   | Yes                                                             |
|                            |                                                        | 2   | No                                                              |
| s1_q5_n_2 (required)       | How many times have you contracted the COVID-19 virus? |     |                                                                 |
| s1_q6 (required)           | Have you been vaccinated                               | 1   | Yes                                                             |
|                            | against COVID-19 yet?                                  | 2   | No                                                              |
| survey > section 1 > s1_g1 |                                                        |     |                                                                 |
| s1_q7 (required)           | Do you recall if you got just                          | 1   | 1                                                               |
|                            | one shot or did you get two?                           | 2   | 2                                                               |
|                            | , ,                                                    | 3   | Something else                                                  |
|                            |                                                        | 888 | Do not recall                                                   |
| s1_q8 (required)           | Which of the following                                 | 1   | Pfizer                                                          |
|                            | vaccines did you receive?                              | 2   | Moderna                                                         |
|                            | ,                                                      | 3   | Novavax                                                         |
|                            |                                                        | 4   | Johnson & Johnson's                                             |
|                            |                                                        |     | Janssen                                                         |
|                            |                                                        | 5   | CanSino                                                         |
|                            |                                                        | 6   | Sputnik                                                         |
|                            |                                                        | 7   | SinoVac                                                         |
|                            |                                                        | 8   | SinoPharm                                                       |
|                            |                                                        | 888 | Do not remember                                                 |
| s1_q9 (required)           | Why did you get vaccinated                             | 1   | To protect against COVID                                        |
|                            | the first time?                                        | 2   | Because I was required to in order go out/attend school or work |
|                            |                                                        | 3   | To protect others                                               |
|                            |                                                        | 4   | Everyone I knew was                                             |
|                            |                                                        | 5   | vaccinating  My doctor told me to do it                         |
|                            |                                                        | 6   | Due to travel reasons                                           |
|                            |                                                        | 777 | Others                                                          |
| s1_q9_o (required)         | Please specify other                                   | 111 | Outers                                                          |
| 1 (1)                      | If no, why haven't you gotten                          | 1   | Concern about side effects                                      |
| s1_q10 (required)          | vaccinated?                                            | 2   | Do not trust the vaccines                                       |
|                            |                                                        | 3   | Wasn't able to get a shot                                       |
|                            |                                                        | 4   | Didn't have time                                                |
|                            |                                                        | 5   | Disease not that bad                                            |
|                            |                                                        | 6   | Against religious beliefs                                       |
|                            |                                                        | 777 | Other                                                           |
| s1_q10_o (required)        | Please specify other                                   |     |                                                                 |

| s1_q11_n (required)         | recommending that everyone                                                   |   | Yes             |
|-----------------------------|------------------------------------------------------------------------------|---|-----------------|
|                             |                                                                              |   | No              |
|                             | over the age of 18 get a COVID-19 booster shot 6 months after they are fully | 2 | Do not recall   |
|                             |                                                                              | 4 | Not applicable  |
|                             |                                                                              | T | 140t applicable |
|                             | vaccinated to maintain their                                                 |   |                 |
|                             | protection against COVID-19. Were you aware of this                          |   |                 |
|                             | recommendation?                                                              |   |                 |
| s1_q11 (required)           | Have you had one booster                                                     | 1 | Yes             |
|                             | shot yet?                                                                    | 2 | No              |
|                             | -                                                                            | 3 | Do not recall   |
|                             |                                                                              | 4 | Not applicable  |
| s1_q13 (required)           | Can I sign you up to get a COVID-19 vaccine or booster                       | 1 | Yes             |
|                             | during your visit today?                                                     | 2 | No              |
| s1_q14 (required)           | 4 (required) Today we are offering a free                                    |   | Yes             |
|                             | COVID-19 vaccination clinic                                                  | 2 | No              |
| right here in the hospital. |                                                                              | _ | 110             |
|                             | can get the COVID-19 vaccine or booster.                                     |   |                 |
|                             | Vaccine of boosters  Vaccination and boosters                                |   |                 |
|                             | may be required for certain                                                  |   |                 |
|                             | travel destinations, work                                                    |   |                 |
|                             | requirements or other types                                                  |   |                 |
|                             | of activities. You just have to                                              |   |                 |
|                             | walk over to a room and they                                                 |   |                 |
|                             | will help register you and                                                   |   |                 |
|                             | administer the shot on spot at                                               |   |                 |
|                             | no cost. Even if you have                                                    |   |                 |
|                             | already been boosted or vaccinated they can check if                         |   |                 |
|                             | you are eligible for another                                                 |   |                 |
|                             | dose.                                                                        |   |                 |
|                             | Can I sign you up to get a                                                   |   |                 |
|                             | COVID-19 vaccine or booster                                                  |   |                 |
|                             | during your visit today?                                                     |   |                 |
| s1_q15 (required)           | Today we are offering a free                                                 | 1 | Yes             |
|                             | COVID-19 vaccination clinic                                                  | 2 | No              |
|                             | right here in the hospital. You                                              | ~ |                 |

|                   | just have to walk over to a room and they will help register you and administer the shot on spot at no cost. You can get the COVID-19 vaccine or booster. The vaccines and boosters are really safe. The overwhelming majority of people experience no side effects and can go about their day as usual. At worst, you might get a mild fever that will be over in a day or two, whereas getting COVID-19 can result in a long hospital stay or death. Elderly people are especially at risk of severe COVID-19 if they have not been boosted and the vaccines are safe for elderly people as well. Even if you have already been boosted or vaccinated they can check if you are eligible for another dose. |            |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
|                   | Can I sign you up to get a COVID-19 vaccine or booster during your visit today?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |
| s1_q16 (required) | Today we are offering a free COVID-19 vaccination clinic right here in the hospital. It is really easy to get vaccinated against COVID-19. You just have to walk over to a room and they will help register you and administer the shot on spot at no cost. You can get the COVID-19 vaccine or booster. The vaccines and booster shots being given today are all Pfizer or Moderna versions not the Chinese or Russian vaccines that were primarily available before. Even if you have already been boosted or vaccinated they can check if you are eligible for another dose.                                                                                                                              | 1 Yes 2 No |

|                    | COVID-19 vaccine or booster during your visit today?                                                                                                                                                                                                                                                                                                                                                                                                            |     |                                     |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-------------------------------------|
| s1_q17 (required)  | Today we are offering a free COVID-19 vaccination clinic right here in the hospital. You just have to walk over to a room and they will help register you and administer the shot on spot at no cost. You can get the COVID-19 vaccine or booster. Even if you have already been boosted or vaccinated they can check if you are eligible for another dose. If you agree to get the vaccine your name will be entered in a lottery, a chance to win PKR 30,000. | 1 2 | Yes                                 |
|                    | Can I sign you up to the COVID-19 vaccine or booster during your visit today?                                                                                                                                                                                                                                                                                                                                                                                   |     |                                     |
| s1_q18 (required)  | What is your mobile number so that we can register you in the raffle?                                                                                                                                                                                                                                                                                                                                                                                           |     |                                     |
| s1_q18a (required) | What is your mobile number?                                                                                                                                                                                                                                                                                                                                                                                                                                     |     |                                     |
| s1_q18n (required) | Network                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 1   | Jazz/Warid                          |
|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 2   | Ufone                               |
|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 3   | Telenor                             |
|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 4   | Zong                                |
| status_survey      | Status of the survey                                                                                                                                                                                                                                                                                                                                                                                                                                            | 1   | Completed                           |
| _                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 2   | Partial Complete                    |
|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 3   | Refused because of time             |
|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 4   | Refused because of lack of interest |
|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 5   | Refused because of lack of trust    |
|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 6   | Refused because of other reasons    |
|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 7   | Unit was locked/empty               |

## Follow-up survey

|                       | Question             | Answer |
|-----------------------|----------------------|--------|
| enum_name (required)  | Conducted By         |        |
| enum_other (required) | Please specify other |        |

| resp_id (required)         | Household ID                                       |   |                                 |
|----------------------------|----------------------------------------------------|---|---------------------------------|
| talk                       | Did someone pick the call?                         | 1 | Yes                             |
|                            |                                                    | 2 | No                              |
| base_info                  | Contact: [contact_b]                               | 1 | Yes                             |
|                            | Gender: [gender_b] Age: [age_b]                    | 2 | No                              |
| survey_confirm (required)  | Did anyone survey you during                       | 1 | Yes                             |
|                            | your visit to Mayo hospital                        | 2 | No                              |
|                            | during the month of December 2022 or January 2023? |   |                                 |
| consent (required)         | Consent Statement                                  |   |                                 |
| Survey                     |                                                    |   |                                 |
| s1_q1                      | Were you offered to get                            | 1 | Yes                             |
|                            | vaccinated on spot?                                | 2 | No                              |
| s1_q2                      | Did you get vaccinated the same day?               | 1 | Yes                             |
|                            |                                                    | 2 | No                              |
| s1_q3                      | Did you get vaccinated many                        | 1 | Yes                             |
|                            | days later?                                        | 2 | No                              |
| s1_q4                      | Have you since then got a                          | 1 | Yes, from Mayo                  |
|                            | booster / vaccine for COVID?                       | 2 | Yes, from other clinic/hospital |
|                            |                                                    | 3 | No                              |
| s1_q5                      | Do you know whether anyone                         | 1 | Yes                             |
|                            | else in your household got                         | 2 | No                              |
|                            | vaccinated/boosted that day at                     | 2 | INO                             |
|                            | Mayo hospital or since that visit?                 |   |                                 |
| s1_q5a                     | Number of members who got vaccinated?              |   |                                 |
| survey > repeat (1)        |                                                    |   |                                 |
| survey > repeat (1) > s1_g |                                                    |   |                                 |
| s1_q6a                     | Who got vaccinated?                                |   |                                 |
|                            | Name                                               |   |                                 |
| s1_q6b                     | Gender who got vaccinated                          | 1 | Male                            |
|                            | 20.740. mis got vaconiated                         | 2 | Female                          |
| s1_q6c                     | Age                                                |   | •                               |
| s1_q7                      | At the hospital that day or                        | 1 | Yes, from Mayo same day         |
|                            | later?                                             | 2 | Yes, from Mayo some             |
|                            |                                                    |   | other day                       |
|                            |                                                    | 3 | Yes, from other clinic hospital |
|                            |                                                    | 4 | No                              |
| status_survey              | Status of the survey                               | 1 | Complete                        |
|                            |                                                    | 2 | Refused                         |
|                            |                                                    | 3 | Partial Refusal                 |
|                            |                                                    | 4 | Did not pick up                 |
|                            |                                                    | 5 | Wrong number                    |

| 6 | Issues with the number |
|---|------------------------|
| 7 | Phone was powered off  |
| 8 | Rescheduled            |
| 9 | Original respondent    |
|   | number was given       |

## Annex C

Table A1: Balance table

|                      |          | (1)           |         | (2)           |         | (3)     |     | (4)     |         | (5)           |
|----------------------|----------|---------------|---------|---------------|---------|---------|-----|---------|---------|---------------|
|                      |          | Control       |         | T1            |         | T2      |     | T3      |         | T4            |
|                      |          | Mean/(        |         | Mean/(        |         | Mean/(  |     | Mean/(  |         | Mean/(        |
| Variables            | N        | SE)           | N       | SE)           | N       | SE)     | Ν   | SE)     | N       | SE)           |
|                      | 29       |               | 31      |               | 30      |         |     |         | 33      |               |
| Age                  | 7        | 42.485        | 4       | 41.981        | 6       | 43.065  | 308 | 43.045  | 3       | 41.652        |
|                      |          | (0.697)       |         | (0.611)       |         | (0.687) |     | (0.663) |         | (0.646)       |
| Gender               |          |               |         |               |         |         |     |         |         |               |
|                      | 29       |               | 31      |               | 30      |         |     |         | 33      |               |
| Male                 | 8        | 0.423         | 8       | 0.346         | 6       | 0.428   | 309 | 0.405   | 3       | 0.441         |
|                      |          | (0.029)       |         | (0.027)       |         | (0.028) |     | (0.028) |         | (0.027)       |
|                      | 29       |               | 31      |               | 30      |         |     |         | 33      |               |
| Female               | 8        | 0.574         | 8       | 0.648         | 6       | 0.569   | 309 | 0.595   | 3       | 0.559         |
|                      |          | (0.029)       |         | (0.027)       |         | (0.028) |     | (0.028) |         | (0.027)       |
| Transmandar          | 29       | 0.000         | 31      | 0.000         | 30      | 0.000   | 200 | 0.000   | 33      | 0.000         |
| Transgender          | 8        | 0.003         | 8       | 0.006         | 6       | 0.003   | 309 | 0.000   | 3       | 0.000         |
|                      | 20       | (0.003)       | 20      | (0.004)       | 20      | (0.003) |     | (0.000) | 22      | (0.000)       |
| Monthly income       | 29<br>1  | 33103.7<br>80 | 30<br>3 | 33575.7<br>76 | 28<br>9 | 78      | 287 | 53      | 32<br>4 | 37163.5<br>80 |
| Wichting Income      | <u> </u> | (621.99       | 3       | (537.70       | 9       | (699.01 | 201 | (844.56 | 4       | (834.85       |
|                      |          | 2)            |         | 9)            |         | 0)      |     | 9)      |         | 6)            |
| Education            |          |               |         |               |         |         |     |         |         |               |
|                      | 29       |               | 31      |               | 30      |         |     |         | 33      |               |
| Did not go to school | 6        | 0.233         | 5       | 0.238         | 5       | 0.200   | 308 | 0.237   | 0       | 0.139         |
|                      |          | (0.025)       |         | (0.024)       |         | (0.023) |     | (0.024) |         | (0.019)       |
|                      | 29       | ,             | 31      |               | 30      | ,       |     |         | 33      | ,             |
| Madrassah            | 6        | 0.108         | 5       | 0.089         | 5       | 0.102   | 308 | 0.065   | 0       | 0.109         |
|                      |          | (0.018)       |         | (0.016)       |         | (0.017) |     | (0.014) |         | (0.017)       |
| Dropped out before   | 29       |               | 31      |               | 30      |         |     |         | 33      |               |
| matric               | 6        | 0.135         | 5       | 0.156         | 5       | 0.154   | 308 | 0.169   | 0       | 0.121         |
|                      |          | (0.020)       |         | (0.020)       |         | (0.021) |     | (0.021) |         | (0.018)       |
|                      | 29       | 0.000         | 31      | 0.005         | 30      | 0.005   | 000 |         | 33      | 0.000         |
| Matric               | 6        | 0.233         | 5       | 0.305         | 5       | 0.325   | 308 | 0.266   | 0       | 0.239         |
|                      |          | (0.025)       | 0.4     | (0.026)       |         | (0.027) |     | (0.025) |         | (0.024)       |
| Intermediate/F.A./F. | 29       | 0.242         | 31      | 0.133         | 30      | 0.424   | 308 | 0.460   | 33      | 0.476         |
| Sc.                  | 6        | 0.213         | 5       | 1             | 5       | 0.134   | 306 | 0.169   | 0       | 0.176         |
|                      | 20       | (0.024)       | 24      | (0.019)       | 20      | (0.020) |     | (0.021) | 22      | (0.021)       |
| Bachelors            | 29<br>6  | 0.071         | 31<br>5 | 0.063         | 30<br>5 | 0.066   | 308 | 0.084   | 33<br>0 | 0.097         |
| Dacrieiois           | 0        |               | 5       |               | 5       |         | 300 |         | U       |               |
| Masters/M.Phil./MBB  | 29       | (0.015)       | 31      | (0.014)       | 30      | (0.014) |     | (0.016) | 33      | (0.016)       |
| S/LLB                | 6        | 0.007         | 5       | 0.016         | 5       | 0.020   | 308 | 0.010   | 0       | 0.118         |
| <u></u>              |          | (0.005)       |         | (0.007)       |         | (0.008) | 000 | (0.006) |         | (0.018)       |
| Vaccinated against   | 29       | (0.003)       | 31      | (0.007)       | 30      | (0.000) |     | (0.000) | 33      | (0.010)       |
| COVID-19 (Yes==1)    | 8        | 0.899         | 8       | 0.893         | 6       | 0.902   | 309 | 0.932   | 3       | 0.856         |
|                      | ļ -      | (0.017)       | Ī       | (0.017)       |         | (0.017) |     | (0.014) |         | (0.019)       |

| Reasons for                        |      | 1       | 1   | ĺ       |    | Í       |     |         |          |         |
|------------------------------------|------|---------|-----|---------|----|---------|-----|---------|----------|---------|
| getting vaccinated                 |      |         |     |         |    |         |     |         |          |         |
| To protect against                 | 26   |         | 28  |         | 27 |         |     |         | 28       |         |
| COVID-19                           | 8    | 0.571   | 4   | 0.595   | 6  | 0.551   | 288 | 0.639   | 5        | 0.523   |
|                                    |      | (0.030) |     | (0.029) |    | (0.030) |     | (0.028) |          | (0.030) |
| Because I was                      |      |         |     |         |    |         |     |         |          |         |
| required to in order               | 26   | 0.057   | 28  | 0.000   | 27 | 0.054   | 000 | 0.004   | 28       | 0.000   |
| to work/ travel                    | 8    | 0.257   | 4   | 0.268   | 6  | 0.254   | 288 | 0.281   | 5        | 0.298   |
|                                    | 00   | (0.027) |     | (0.026) | 07 | (0.026) |     | (0.027) | 00       | (0.027) |
| To protect others                  | 26   | 0.175   | 28  | 0.173   | 27 | 0.167   | 200 | 0.226   | 28       | 0.225   |
| To protect others                  | 8    |         | 4   |         | 6  |         | 288 |         | 5        |         |
| Everyone I knew                    | 26   | (0.023) | 28  | (0.022) | 27 | (0.022) |     | (0.025) | 28       | (0.025) |
| was vaccinating                    | 8    | 0.104   | 4   | 0.116   | 6  | 0.101   | 288 | 0.104   | 5        | 0.144   |
| wao vacomating                     |      | (0.019) | •   | (0.019) |    | (0.018) | 200 | (0.018) | <u> </u> | (0.021) |
| My doctor told me to               | 26   | (0.013) | 28  | (0.013) | 27 | (0.010) |     | (0.010) | 28       | (0.021) |
| do it                              | 8    | 0.075   | 4   | 0.056   | 6  | 0.087   | 288 | 0.038   | 5        | 0.067   |
|                                    |      | (0.016) |     | (0.014) |    | (0.017) |     | (0.011) |          | (0.015) |
| Due to travel                      | 26   | ,       | 28  |         | 27 |         |     |         | 28       |         |
| reasons                            | 8    | 0.082   | 4   | 0.085   | 6  | 0.083   | 288 | 0.063   | 5        | 0.091   |
|                                    |      | (0.017) |     | (0.017) |    | (0.017) |     | (0.014) |          | (0.017) |
| Reasons for not getting vaccinated |      |         |     |         |    |         |     |         |          |         |
| Concern about side                 |      |         |     |         |    |         |     |         |          |         |
| effects                            | 30   | 0.733   | 34  | 0.824   | 30 | 0.667   | 21  | 0.571   | 48       | 0.667   |
|                                    |      | (0.082) |     | (0.066) |    | (0.088) |     | (0.111) |          | (0.069) |
| Do not trust the                   | 00   | 0.000   |     | 0.047   | 00 | 0.500   |     | 0.007   | 40       | 0.040   |
| vaccines                           | 30   | 0.633   | 34  | 0.647   | 30 | 0.500   | 21  | 0.667   | 48       | 0.813   |
| Man and able to and                |      | (0.089) |     | (0.083) |    | (0.093) |     | (0.105) |          | (0.057) |
| Was not able to get a shot         | 30   | 0.067   | 34  | 0.029   | 30 | 0.033   | 21  | 0.048   | 48       | 0.104   |
| 4 01101                            | - 00 | (0.046) |     | (0.029) | 00 | (0.033) |     | (0.048) | 1.0      | (0.045) |
| Did not have time                  | 30   | 0.000   | 34  | 0.000   | 30 | 0.000   | 21  | 0.000   | 48       | 0.021   |
| Dia not nave time                  | 30   | (0.000) | J-T | (0.000) | 30 | (0.000) | 21  | (0.000) | 70       | (0.021) |
| Disease not that bad               | 30   | 0.000   | 34  | 0.000   | 30 | 0.033   | 21  | 0.048   | 48       | 0.000   |
| Disease not that bau               | 30   |         | 34  |         | 30 | 1       | 21  | (0.048) | 40       | (0.000) |
| Against religious                  |      | (0.000) |     | (0.000) |    | (0.033) |     | (0.040) |          | (0.000) |
| beliefs                            | 30   | 0.000   | 34  | 0.000   | 30 | 0.000   | 21  | 0.000   | 48       | 0.000   |
|                                    |      | (0.000) |     | (0.000) | 1  | (0.000) |     | (0.000) |          | (0.000) |
| Others                             | 30   | 0.100   | 34  | 0.029   | 30 | 0.133   | 21  | 0.095   | 48       | 0.000   |
| 341010                             | - 50 | (0.056) | J-  | (0.029) | 50 | (0.063) |     | (0.066) |          | (0.000) |
|                                    | ]    | (0.000) | 1   | (0.023) | 1  | (0.003) | 1   | (0.000) | 1        | (0.000) |


Table A2: Balance table , pairwise t-tests

| (C)-(T1) | (C)-(T2) | (C)-(T3) | (C)-(T4)    |
|----------|----------|----------|-------------|
| Pairwise | Pairwise | Pairwise | Pairwise t- |
| t-test   | t-test   | t-test   | test        |

|                                        |      | Mean<br>differenc |     | Mean<br>differenc |     | Mean<br>differenc |     | Mean       |
|----------------------------------------|------|-------------------|-----|-------------------|-----|-------------------|-----|------------|
| Variables                              | N    | е                 | N   | е                 | N   | е                 | N   | difference |
| Age                                    | 611  | 0.504             | 603 | -0.581            | 605 | -0.561            | 630 | 0.833      |
|                                        |      |                   |     |                   |     |                   |     |            |
| Gender                                 |      |                   |     |                   |     |                   |     |            |
| Male                                   | 616  | 0.077**           | 604 | -0.005            | 607 | 0.018             | 631 | -0.019     |
|                                        |      |                   |     |                   |     |                   |     |            |
| Female                                 | 616  | -0.074*           | 604 | 0.005             | 607 | -0.022            | 631 | 0.015      |
|                                        |      |                   |     |                   |     |                   |     |            |
| Transgender                            | 616  | -0.003            | 604 | 0.000             | 607 | 0.003             | 631 | 0.003      |
| Transgender                            | 010  | -0.003            | 004 | 0.000             | 007 | 0.003             | 031 | 0.003      |
|                                        |      |                   |     |                   |     | -                 |     | -          |
|                                        |      |                   |     |                   |     | 1306.67           |     | 4059.800*  |
| Monthly income                         | 594  | -471.996          | 580 | -193.798          | 578 | 3                 | 615 | **         |
|                                        |      |                   |     |                   |     |                   |     |            |
| Education                              |      |                   |     |                   |     |                   |     |            |
| Did not go to school                   | 611  | -0.005            | 601 | 0.033             | 604 | -0.004            | 626 | 0.094***   |
|                                        |      |                   |     |                   |     |                   |     |            |
| Madrassah                              | 611  | 0.019             | 601 | 0.006             | 604 | 0.043*            | 626 | -0.001     |
| ······································ | 0    | 0.0.0             |     | 0.000             |     | 0.0.0             |     | 0.00.      |
| Dropped out before                     |      |                   |     |                   |     |                   |     |            |
| matric                                 | 611  | -0.020            | 601 | -0.019            | 604 | -0.034            | 626 | 0.014      |
|                                        |      |                   |     |                   |     |                   |     |            |
| Matric                                 | 611  | -0.072**          | 601 | -0.091**          | 604 | -0.033            | 626 | -0.006     |
|                                        |      |                   |     |                   |     |                   |     |            |
| Intermediate/F.A./F.Sc                 | 611  | 0.080***          | 601 | 0.078**           | 604 | 0.044             | 626 | 0.037      |
| miorinodiato/1 :/ t./1 :00             | 011  | 0.000             | 001 | 0.070             | 001 | 0.011             | 020 | 0.007      |
| Doobolore                              | C4.4 | 0.007             | 004 | 0.005             | CO4 | 0.042             | coc | 0.000      |
| Bachelors                              | 611  | 0.007             | 601 | 0.005             | 604 | -0.013            | 626 | -0.026     |
| Masters/M.Phil./MBBS/L                 |      |                   |     |                   |     |                   |     |            |
| LB                                     | 611  | -0.009            | 601 | -0.013            | 604 | -0.003            | 626 | -0.111***  |
| Vaccinated against                     |      |                   |     |                   |     |                   |     |            |
| <b>COVID-19</b> (Yes==1)               | 616  | 0.006             | 604 | -0.003            | 607 | -0.003            | 631 | 0.043*     |
| December of the second second          |      |                   |     |                   |     |                   |     |            |
| Reasons for getting vaccinated         |      |                   |     |                   |     |                   |     |            |
| To protect against                     |      |                   |     |                   |     |                   |     |            |
| COVID-19                               | 552  | -0.024            | 544 | 0.020             | 556 | -0.068            | 553 | 0.048      |
|                                        |      |                   |     |                   |     |                   |     |            |
| Because I was required                 |      |                   |     |                   |     |                   |     |            |
| to in order to work/<br>travel         | 552  | -0.010            | 544 | 0.004             | 556 | -0.024            | 553 | -0.041     |
|                                        |      | 111.0             |     | 1                 |     |                   |     |            |
|                                        | 1    | 1                 | 1   | <u> </u>          | 1   | 1                 | 1   | 1          |

| 552 | 0.003                                     | 544                                                                             | 0.009                                                                                                         | 556                                                                                                                                                                                                                                                                                                                                                                                           | -0.050                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 553                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | -0.049                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----|-------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|     |                                           |                                                                                 |                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 552 | -0.012                                    | 544                                                                             | 0.003                                                                                                         | 556                                                                                                                                                                                                                                                                                                                                                                                           | 0.000                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 553                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | -0.039                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|     |                                           |                                                                                 |                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 552 | 0.018                                     | 544                                                                             | -0.012                                                                                                        | 556                                                                                                                                                                                                                                                                                                                                                                                           | 0.036*                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 553                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0.008                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 552 | -0.002                                    | 544                                                                             | -0.001                                                                                                        | 556                                                                                                                                                                                                                                                                                                                                                                                           | 0.020                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 553                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | -0.009                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|     |                                           |                                                                                 |                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 64  | -0.090                                    | 60                                                                              | 0.067                                                                                                         | 51                                                                                                                                                                                                                                                                                                                                                                                            | 0.162                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 78                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.067                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|     |                                           |                                                                                 |                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 64  | -0.014                                    | 60                                                                              | 0.133                                                                                                         | 51                                                                                                                                                                                                                                                                                                                                                                                            | -0.033                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 78                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | -0.179*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 64  | 0.037                                     | 60                                                                              | 0.033                                                                                                         | 51                                                                                                                                                                                                                                                                                                                                                                                            | 0.019                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 78                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | -0.037                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| .n  | .n                                        | .n                                                                              | .n                                                                                                            | .n                                                                                                                                                                                                                                                                                                                                                                                            | .n                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 78                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | -0.021                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|     |                                           |                                                                                 |                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| .n  | .n                                        | 60                                                                              | -0.033                                                                                                        | 51                                                                                                                                                                                                                                                                                                                                                                                            | -0.048                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | .n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | .n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| .n  | .n                                        | .n                                                                              | .n                                                                                                            | .n                                                                                                                                                                                                                                                                                                                                                                                            | .n                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | .n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | .n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 64  | 0.071                                     | 60                                                                              | -0.033                                                                                                        | 51                                                                                                                                                                                                                                                                                                                                                                                            | 0.005                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 78                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.100**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|     | 552<br>552<br>552<br>64<br>64<br>.n<br>.n | 552 -0.012  552 0.018  552 -0.002  64 -0.090  64 -0.014  64 0.037  .n .n  .n .n | 552 -0.012 544  552 0.018 544  552 -0.002 544  64 -0.090 60  64 -0.014 60  64 0.037 60  .n .n .n .n  .n .n .n | 552       -0.012       544       0.003         552       0.018       544       -0.012         552       -0.002       544       -0.001         64       -0.090       60       0.067         64       -0.014       60       0.133         64       0.037       60       0.033         .n       .n       .n       .n         .n       .n       .n       .n         .n       .n       .n       .n | 552       -0.012       544       0.003       556         552       0.018       544       -0.012       556         552       -0.002       544       -0.001       556         64       -0.090       60       0.067       51         64       -0.014       60       0.133       51         .n       .n       .n       .n       .n         .n       .n       .n       .n       .n         .n       .n       .n       .n       .n         .n       .n       .n       .n       .n | 552       -0.012       544       0.003       556       0.000         552       0.018       544       -0.012       556       0.036*         552       -0.002       544       -0.001       556       0.020         64       -0.090       60       0.067       51       0.162         64       -0.014       60       0.133       51       -0.033         64       0.037       60       0.033       51       0.019         .n       .n       .n       .n       .n       .n       .n         .n       .n       .n       .n       .n       .n       .n         .n       .n       .n       .n       .n       .n       .n | 552       -0.012       544       0.003       556       0.000       553         552       0.018       544       -0.012       556       0.036*       553         552       -0.002       544       -0.001       556       0.020       553         64       -0.090       60       0.067       51       0.162       78         64       -0.014       60       0.133       51       -0.033       78         64       0.037       60       0.033       51       0.019       78         .n       .n       .n       .n       .n       .n         .n       .n       .n       .n       .n |

Figure A1: OLS regression model showing relationship between treatment arms and willingness to register for getting vaccinated



Note: **T1** (Vaccine Mandates), **T2** (Side-effects minimization, **T3** (Manufacturer of the vaccine), **T4** (Lottery).

**Table A3:** OLS regression model showing relationship between treatment arms and willingness to register for getting vaccinated

|                                  | Willingness to register for<br>getting vaccinated |
|----------------------------------|---------------------------------------------------|
| Variables                        | OLS                                               |
| T1 (Vaccine Mandates)            | 0.073***                                          |
|                                  | (0.023)                                           |
|                                  | [0.028, 0.118]                                    |
| T2 (Side-effects minimization)   | 0.071***                                          |
|                                  | (0.022)                                           |
|                                  | [0.028, 0.114]                                    |
| T3 (Manufacturer of the vaccine) | 0.022                                             |
|                                  | (0.019)                                           |
|                                  | [-0.014, 0.059]                                   |
| T4 (Lottery)                     | 0.352***                                          |
|                                  | (0.030)                                           |
|                                  | [0.293, 0.411]                                    |
|                                  |                                                   |

Gender

Female Ref Male 0.029

(0.021)

[-0.011, 0.070]

Age (years) -0.002\*\*

(0.001)

[-0.004, -0.000]

Monthly household income

(logged) 0.150\*\*\*

(0.029)

[0.092, 0.207]

Language

Punjabi/Urdu Ref Sindhi and others\* -0.053 (0.033)

[-0.118, 0.012]

**Education** 

Did not go to school Ref
Madrassah 0.046

(0.040)

[-0.032, 0.123]

Dropped out before Matric 0.034

(0.025)

[-0.014, 0.082]

Matric 0.074\*\*\*

(0.027)

[0.022, 0.126]

Intermediate/F.A./F.Sc. 0.095\*\*\*

(0.031)

[0.035, 0.154]

Bachelors 0.160\*\*\*

(0.041)

[0.079, 0.241]

Masters/ M.Phil./ MBBS / LLB 0.297\*\*\*

(0.068)

[0.164, 0.429]

Reasons for getting vaccinated

To protect against COVID-19 0.054\*\*

(0.024)

[0.008, 0.100]

Required in order to go out/attend

school or work -(

-0.031

(0.025)

[-0.080, 0.017]

To protect others -0.045\*\*

(0.021)

[-0.087, -0.004]

Everyone I knew was vaccinating -0.041

(0.031)

[-0.101, 0.020]

My doctor told me to do it -0.067\*

(0.040)

[-0.145, 0.011]

Travel reasons -0.021

(0.034)

[-0.088, 0.046]

Constant -1.520\*\*\*

(0.307)

[-2.122, -0.918]

Observations 1334

Note: Robust standard errors in parentheses. \* p<0.1, \*\* p<0.05, \*\*\* p<0.01.


\*Others include: Pushto, Balochi and Siraki and others.

Table A4: Follow up survey - respondents who got the booster shot by treatment groups

|                    | Total    | Control | T1      | T2      | T3      | T4       |
|--------------------|----------|---------|---------|---------|---------|----------|
|                    | (n= 744) | (n=140) | (n=141) | (n=131) | (n=164) | (n=168)  |
| Got vaccinated the | 10       | 3       | 1       | 2       | 2       | 2        |
| same day           | (1.36%)  | (2.21)  | (0.71%) | (1.54%) | (1.23%) | (1.21%)  |
| Got vaccinated     | 51       | 3       | 7       | 1       | 4       | 36       |
| many days later    | (7.08%)  | (2.26%) | (5.07%) | (0.79%) | (2.50%) | (22.22%) |

Note: Data are n (%). **T1** (Vaccine Mandates), **T2** (Side-effects minimization, **T3** (Manufacturer of the vaccine), **T4** (Lottery).

**Figure A2:** Follow up survey - OLS regression model sho`wing relationship between treatment arms and vaccination status: (i) Got vaccinated the same day (ii) Got vaccinated many days later



Note: **T1** (Vaccine Mandates), **T2** (Side-effects minimization, **T3** (Manufacturer of the vaccine), **T4** (Lottery).



www.theigc.org